Jeff Garro
Stock Analyst at Stephens & Co.
(1.34)
# 3,220
Out of 4,829 analysts
49
Total ratings
33.33%
Success rate
-12.21%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Reiterates: Equal-Weight | $28 | $26.27 | +6.59% | 3 | Apr 10, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $241.44 | +15.97% | 2 | Mar 6, 2025 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $5 | $4.52 | +10.62% | 4 | Mar 6, 2025 | |
| CERT Certara | Reiterates: Overweight | $17 | $12.13 | +40.15% | 5 | Feb 27, 2025 | |
| EVH Evolent Health | Maintains: Equal-Weight | $16 → $12 | $9.31 | +28.89% | 5 | Jan 21, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $26 | $25.06 | +3.75% | 3 | Jan 7, 2025 | |
| DH Definitive Healthcare | Initiates: Equal-Weight | $5 | $3.58 | +39.66% | 1 | Dec 20, 2024 | |
| DOCS Doximity | Initiates: Equal-Weight | $55 | $61.04 | -9.90% | 1 | Dec 20, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $5.5 | $9.20 | -40.22% | 3 | Dec 20, 2024 | |
| IQV IQVIA Holdings | Initiates: Overweight | $250 | $156.13 | +60.12% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $15.19 | +11.92% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $30.82 | +26.54% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 | $26.05 | +7.49% | 8 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $7.35 | +280.95% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $14.92 | +34.05% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $3.79 | +2.90% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.35 | +27.66% | 3 | May 6, 2022 |
TruBridge
Apr 10, 2025
Reiterates: Equal-Weight
Price Target: $28
Current: $26.27
Upside: +6.59%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $241.44
Upside: +15.97%
Health Catalyst
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.52
Upside: +10.62%
Certara
Feb 27, 2025
Reiterates: Overweight
Price Target: $17
Current: $12.13
Upside: +40.15%
Evolent Health
Jan 21, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $9.31
Upside: +28.89%
Privia Health Group
Jan 7, 2025
Reiterates: Overweight
Price Target: $26
Current: $25.06
Upside: +3.75%
Definitive Healthcare
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5
Current: $3.58
Upside: +39.66%
Doximity
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $61.04
Upside: -9.90%
OptimizeRx
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5.5
Current: $9.20
Upside: -40.22%
IQVIA Holdings
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $156.13
Upside: +60.12%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $15.19
Upside: +11.92%
Nov 15, 2024
Initiates: Overweight
Price Target: $39
Current: $30.82
Upside: +26.54%
May 31, 2024
Reiterates: Overweight
Price Target: $28
Current: $26.05
Upside: +7.49%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $7.35
Upside: +280.95%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $14.92
Upside: +34.05%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $3.79
Upside: +2.90%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $2.35
Upside: +27.66%